These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 24833855)

  • 1. Attempts to enhance the eradication rate of Helicobacter pylori infection.
    Bang CS; Baik GH
    World J Gastroenterol; 2014 May; 20(18):5252-62. PubMed ID: 24833855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand.
    Prapitpaiboon H; Mahachai V; Vilaichone RK
    Asian Pac J Cancer Prev; 2015; 16(10):4353-6. PubMed ID: 26028098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Helicobacter pylori: management in 2013.
    Alahdab YO; Kalayci C
    World J Gastroenterol; 2014 May; 20(18):5302-7. PubMed ID: 24833860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
    Fiorini G; Zullo A; Saracino IM; Gatta L; Pavoni M; Vaira D
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):621-625. PubMed ID: 29481383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Helicobacter pylori infection: current status and future concepts.
    Yang JC; Lu CW; Lin CJ
    World J Gastroenterol; 2014 May; 20(18):5283-93. PubMed ID: 24833858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2C19 polymorphism influences Helicobacter pylori eradication.
    Kuo CH; Lu CY; Shih HY; Liu CJ; Wu MC; Hu HM; Hsu WH; Yu FJ; Wu DC; Kuo FC
    World J Gastroenterol; 2014 Nov; 20(43):16029-36. PubMed ID: 25473155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.
    Gisbert JP; Barrio J; Modolell I; Molina-Infante J; Aisa AP; Castro-Fernández M; Rodrigo L; Cosme A; Gisbert JL; Fernández-Bermejo M; Marcos S; Marín AC; McNicholl AG
    Dig Dis Sci; 2015 Feb; 60(2):458-64. PubMed ID: 25236423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
    Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance.
    Papastergiou V; Georgopoulos SD; Karatapanis S
    World J Gastroenterol; 2014 Aug; 20(29):9898-911. PubMed ID: 25110420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seven-day triple therapy is a better choice for Helicobacter pylori eradication in regions with low antibiotic resistance.
    Tong YF; Lv J; Ying LY; Xu F; Qin B; Chen MT; Meng F; Tu MY; Yang NM; Li YM; Zhang JZ
    World J Gastroenterol; 2015 Dec; 21(46):13073-9. PubMed ID: 26672777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
    Greenberg ER; Anderson GL; Morgan DR; Torres J; Chey WD; Bravo LE; Dominguez RL; Ferreccio C; Herrero R; Lazcano-Ponce EC; Meza-Montenegro MM; Peña R; Peña EM; Salazar-Martínez E; Correa P; Martínez ME; Valdivieso M; Goodman GE; Crowley JJ; Baker LH
    Lancet; 2011 Aug; 378(9790):507-14. PubMed ID: 21777974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy.
    Prasertpetmanee S; Mahachai V; Vilaichone RK
    Helicobacter; 2013 Aug; 18(4):270-3. PubMed ID: 23356886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study.
    Phiphatpatthamaamphan K; Vilaichone RK; Siramolpiwat S; Tangaroonsanti A; Chonprasertsuk S; Bhanthumkomol P; Pornthisarn B; Mahachai V
    Asian Pac J Cancer Prev; 2016; 17(4):1903-7. PubMed ID: 27221874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel and Effective Therapeutic Regimens for
    Hu Y; Zhu Y; Lu NH
    Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
    [No Abstract]   [Full Text] [Related]  

  • 16. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance.
    Long X; Chen Q; Yu L; Liang X; Liu W; Lu H
    Helicobacter; 2018 Jun; 23(3):e12485. PubMed ID: 29696736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial.
    Zhou L; Zhang J; Song Z; He L; Li Y; Qian J; Bai P; Xue Y; Wang Y; Lin S
    Helicobacter; 2016 Apr; 21(2):91-9. PubMed ID: 26104022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple-antibiotic-resistant Helicobacter pylori infection eradicated with a tailor-made quadruple therapy.
    Nakajima S; Inoue H; Inoue T; Maruoka Y
    J Gastroenterol Hepatol; 2012 Apr; 27 Suppl 3():108-11. PubMed ID: 22486882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.
    Saito Y; Serizawa H; Kato Y; Nakano M; Nakamura M; Saito H; Suzuki H; Kanai T
    World J Gastroenterol; 2015 Dec; 21(48):13548-54. PubMed ID: 26730167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection.
    Liou JM; Chen PY; Luo JC; Lee JY; Chen CC; Fang YJ; Yang TH; Chang CY; Bair MJ; Chen MJ; Hsu YC; Hsu WF; Chang CC; Lin JT; Shun CT; El-Omar EM; Wu MS;
    Gastroenterology; 2018 Oct; 155(4):1109-1119. PubMed ID: 29964036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.